References 1 Gardner WN, Meah M. Bass C. Controlled study of respiratory responses during prolonged measurement in pateints with chronic hyperventilation. Lancet 1986;ii: 826-30 2 Bass C, Gardner WN. Respiratory and psychiatric abnormalities in chronic symptomatic hyperventilation. Br Med J 1985; 290:1387- investigation. This was the situation deplored 50 years ago by Kerr et al.3:' They are often shunted from one physician to another, and the sins of commission inflicted upon them fill many black pages in our book of achievement'. My laboratory was specifically orientated to the evaluation of airway obstruction and, working in close collaboration with the cardiac unit, we were well aware of the coexistence of hyperventilation with myocardial disease" as well as asthma. This is not the place to argue the flaws in the paper by Dent et al. purporting to show that the HVS did not exist. After further experience these workers admitted the diagnosis in 20% of their cases", Bass et al. insist that HV must be defined by an arbitrary value for Pco.. They ignore the fact that it is also defined by respiratory alkalosis. The latter occurs, even within the normal reference range for Pco., whenever this is temporarily displaced below the prevailing level, leaving an excess of bicarbonate ion -by definition, respiratory alkalosis. Given the views in their letter, it is surprising to find the following statement from the same team": 'The hyperventilation syndrome is probably one of the most common psychophysiological reactions encountered by physicians ... Despite its prevalence, hyperventilation is seldom recognized ... Patients are often subjected to years of expensive and often invasive investigations ... before the true nature of their illness is recognized'; and 'Spot measurement of arterial or end-tidal Peo 2 shows hypocapnia (less than 30 mmHg) in only a minority of cases'. Papers such as theirs serve only to perpetuate failure to recognize the syndrome. 
Beta-blockers in myocardial infarction
Sir, I was interested to read Dr Greenbaum's editorial (July JRSM, p 402) on the routine use of betablockers in patients who have survived myocardial infarction (MI). There have been 28 studies using intravenous beta-blockade started within 24 hours of the onset of the first symptoms of acute MI. An overview, or meta-analysis of the results from these 28 trials reveals that after only one week of treatment the mortality is reduced by about 14% 1.2 •.If this find. ing is extrapolated to the 100 360 patients adniitted to hospital in England and Wales in 1981with acute Ml, some 3500 lives might be saved, with the hospital more tality dropping from 25% to under 22%3. However, up to two-thirds of all patients admitted will either have contraindications to beta-blockade or will have passed the time period in which beta-blockers are of most potential benefit", Thus only 1200 deaths will be averted, giving a drop in mortality of under 2%, comparable with the reduction in mortality achieved by one year of beta-blocker therapy after MI. The cost of treating a patient for one week with atenolol (the drug for which the greatest benefit has been shown) is £3.55 (atenolol 10mg intravenously once, plus 100mg atenolol orally daily)", This is less than one-tenth of the cost oftreating a patient after a MI with beta-blockers for a year and a mere drop in the ocean compared to the vast expenses ofthrombolytic therapy for MI. Early intervention with betablockers precludes neither long-term beta-blockade nor stopping smoking, and optimum therapy for many patients will involve all three of these treatment methods.
Book reviews
Rights and Wrongs in Medicine -King's College Studies 1981H1 P Byrne (ed) pp 199 £12.95 ISBN Q-19-724637""() London: King Edward's Hospital Fund1986 I approached this book with a degree of trepidation, reading it out of duty rather than anticipated pleasure. I very quickly changed my mind and became so engrossed that at one stage I missed my stop on the Underground and arrived late at a meeting. My problem, therefore, in writing this review is to try to persuade busy clinicians, without time to do any reading even around their own subjects, to put time aside to read this book on different aspects of medical ethics as far removed from their immediate concerns as in vitro fertilization and the health hazards of employment.
The book consists of a variety of essays addressing up-to-the minute issues of medical law and medical ethics. It is a pity we are not informed about the background and qualifications of the authors, but I was able to guess that Sir Immanual Jakabovits is the ChiefRabbi and I happen to be personally acquainted with Ian Kennedy, Professor of Medical Law and Ethics at King's College London.
Most authors have managed to strike a happy balance of wit without trivialization, and seriousness without lapsing into sanctimony. I was familiar with some of the ethical dilemmas discussed, such as the issues of consent and the debate concerning the sanctity of the embryo. However, I must confess ignorance about the fine distinction between 'a person' and 'a member of the human species'.
The book is the first of a series to be produced annually by the Centre for Medical Law and Ethics at King's College London, and for that reason starts off with two chapters surveying the issues of the past year, including the Sidaway case (consent to surgery with the knowledge of remote risks), the Gillick case (prescription of contraceptives to under-age girls), Even if Dr Greenbaum's patients will not be receiving long-term beta-blockade, at least some, I hope, will receive beta-blockers while in hospital so that more may survive to stop smoking. S H S PEARCE
